Commercialisation. The Licensee shall use its commercially reasonable endeavours to develop a therapeutic product to deliver Complement Factors via sub-retinal injection of adeno-associated virus (AAV) and shall report annually on this effort.
Appears in 2 contracts
Sources: Exclusive Patent Licence Agreement (Gyroscope Therapeutics Holdings LTD), Exclusive Patent Licence Agreement (Gyroscope Therapeutics Holdings LTD)